Dogecoin Cash, Inc. Reports Slight Revenue Increase in Q3 2025 Amid Ongoing Challenges

Dogecoin Cash, Inc. reported a slight increase in revenue for the third quarter of 2025, with figures reaching $190,564, a 1% rise compared to $189,121 in the same period of 2024. The cost of revenues as a percentage of sales decreased by 2%, reflecting improved efficiency. The revenue growth was primarily driven by an uptick in patient certifications through PrestoDoctor, attributed to recent state-market expansions, new referral arrangements with retailers, and enhanced marketing initiatives. However, for the nine months ending September 30, 2025, revenue decreased by 13% to $567,501 from $648,643 in the prior year, largely due to increased competition in the cannabis telemedicine sector.

The company's gross profit for the nine-month period also saw a decline, falling to $360,392 from $395,274, marking a 9% decrease. Total operating expenses decreased significantly by 17% to $792,591, down from $949,857 in the previous year. This reduction was driven by lower professional fees, depreciation and amortization, wages and salaries, and advertising expenses. Notably, professional fees dropped by 43%, and wages and salaries decreased by 23%, reflecting ongoing cost-management efforts and reduced staffing levels. The net loss for the period from continuing operations improved to $(432,199) from $(554,583), a 22% reduction.

Operationally, Dogecoin Cash, Inc. has been focusing on strategic developments, including the acquisition of DogeSPAC LLC, which provided the company with 600 million Dogecoin Cash tokens. The company also issued 4,200,000 shares of common stock in exchange for an additional 420 million Dogecoin Cash tokens. Despite these acquisitions, the company reported an impairment expense of $7,079,850 related to the digital currency, reflecting the volatility and instability in the cryptocurrency market. The company ended the third quarter with $29,978 in cash, indicating liquidity challenges as it seeks to raise capital for ongoing operations.

The company’s accumulated deficit reached $84,305,776 as of September 30, 2025, raising concerns about its ability to continue as a going concern. Management indicated that future operations depend on generating profitable operations and obtaining necessary financing. The company may pursue public or private offerings of equity capital or convertible debt to bolster its working capital. However, such actions could lead to dilution for current shareholders.

Looking ahead, Dogecoin Cash, Inc. remains focused on expanding its market presence and enhancing its service offerings through PrestoDoctor. The management is optimistic about future growth opportunities, particularly in light of recent state-market expansions and new partnerships. However, the competitive landscape in the cannabis telemedicine industry poses ongoing challenges that the company will need to navigate carefully.